4iP News

Registration open for our next webinar ! IP from the perspective of a venture capitalist

22 October 2019

With Dr. Christian Schneider on 21 November at 16-17.00 CET

Join this webinar to hear the perspective of an experienced venture capitalist on start-up selection and the role of intellectual property. Christian will draw upon his experience as a seasoned investor over 20 years to give a picture of common patterns and challenges inventors and entrepreneurs experience with regard to intellectual property. The webinar will draw upon experience and examples from the bio-tech sector but is relevant to people from all sectors.

Attendees may want to explore 4iP Council's interactive guides on intellectual property types and benefits prior to the webinar.

Register here

This 4iP Council webinar will address the following:

  • The range of attributes investors look for
  • The role of IP in investment decision-making
  • Pitfalls and challenges in relation to IP
  • Real world examples – good and bad


Dr. Christian Schneider is a Managing Partner of Vesalius Biocapital and has been a venture capital executive for the past 20 years. As a life science expert, he has extensive hands-on work and investment experience in the areas of diagnostics, medtech, and therapeutics. As shareholder and board member he actively supports and advises start-up companies.

Starting as an R&D scientist at Boehringer Mannheim / Roche, he developed automated tests for the early detection of cancer. At Centocor, he led diagnostic product development in transatlantic collaborations. Later, as a business developer and external research manager in Centocor’s / Johnson&Johnson’s biological therapeutics business, he negotiated, financed, and managed international early-stage product development projects.

As a Managing Partner of venture capital firm PolyTechnos, he was directly responsible for the investments in and IPOs of OncoMethylome Sciences (Euronext, 2006), Devgen (Euronext, 2005) and Jerini (Frankfurt, 2005) and served as an independent director on the boards of Hepa Wash and MagnaMedics. In 2008, he joined the pan-European life science venture capital firm Vesalius Biocapital as a Managing Partner with responsibility for the investments and exits of Skyline (write-off) and Activaero (EUR 130m trade sale to Vectura, 2014). Across three Vesalius fund generations, he is currently responsible for portfolio companies Ventaleon, Omeicos, Humedics, Softhale and Mecuris.

Dr. Schneider holds a doctorate degree in veterinary medicine (1992) and a PhD in immunology (1995), both from the University of Munich, Germany, and an MBA in healthcare administration from Penn State University, Pennsylvania (1999).